Back to the Beginning: The Role of Ovarian Suppression in Management of Hormone Sensitive Breast Cancer in Premenopausal Women
Menée à partir des données de deux essais incluant un total de 4 690 atteintes d'un cancer du sein de stade précoce avant la ménopause (durée médiane de suivi : 13 ans), cette étude compare l'efficacité, du point de vue de la survie sans maladie, du délai sans récidive distante et de la survie globale, et la toxicité de l'exémestane et du tamoxifène, dispensés en traitement adjuvant avec une suppression de la fonction ovarienne
Although many consider targeted therapy a modern concept, targeted therapy in breast cancer dates back to 1889, when Schinzinger first proposed oophorectomy as adjunctive therapy for breast cancer to alter the hormonal milieu of the malignancy. Beatson put the proposal into practice, reporting decreases in cutaneous metastases in a premenopausal woman after oophorectomy in 1896. The mechanism underlying the response to oophorectomy remained mysterious until Jenson identified the estrogen receptor (ER) 75 years later. Since that time, the ER has become the most well-studied, and arguably the most important, target for breast cancer therapy.
Journal of Clinical Oncology , éditorial, 2021